

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 8, 2002, 22:23:50 ; Search time 37.6 Seconds
(without alignments)
892.426 Million cell updates/sec

Title: US-09-635-521A-2
Perfect score: 2334
Sequence: 1 MASPSIPGSDCSQIIDSHV.....NSGAKPANSAAENGQHEHV 453

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 522463 seqs, 74073290 residues
Total number of hits satisfying chosen parameters: 522463

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: /SIDB2/gcgdata/geneseq/geneseq/AA1980.DAT:*
2: /SIDB2/gcgdata/geneseq/geneseq/AA1981.DAT:*
3: /SIDB2/gcgdata/geneseq/geneseq/AA1982.DAT:*
4: /SIDB2/gcgdata/geneseq/geneseq/AA1983.DAT:*
5: /SIDB2/gcgdata/geneseq/geneseq/AA1984.DAT:*
6: /SIDB2/gcgdata/geneseq/geneseq/AA1985.DAT:*
7: /SIDB2/gcgdata/geneseq/geneseq/AA1986.DAT:*
8: /SIDB2/gcgdata/geneseq/geneseq/AA1987.DAT:*
9: /SIDB2/gcgdata/geneseq/geneseq/AA1988.DAT:*
10: /SIDB2/gcgdata/geneseq/geneseq/AA1989.DAT:*
11: /SIDB2/gcgdata/geneseq/geneseq/AA1990.DAT:*
12: /SIDB2/gcgdata/geneseq/geneseq/AA1991.DAT:*
13: /SIDB2/gcgdata/geneseq/geneseq/AA1992.DAT:*
14: /SIDB2/gcgdata/geneseq/geneseq/AA1993.DAT:*
15: /SIDB2/gcgdata/geneseq/geneseq/AA1994.DAT:*
16: /SIDB2/gcgdata/geneseq/geneseq/AA1995.DAT:*
17: /SIDB2/gcgdata/geneseq/geneseq/AA1996.DAT:*
18: /SIDB2/gcgdata/geneseq/geneseq/AA1997.DAT:*
19: /SIDB2/gcgdata/geneseq/geneseq/AA1998.DAT:*
20: /SIDB2/gcgdata/geneseq/geneseq/AA1999.DAT:*
21: /SIDB2/gcgdata/geneseq/geneseq/AA2000.DAT:*
22: /SIDB2/gcgdata/geneseq/geneseq/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	852	36.5	167	21	Gene 28 human secr
2	852	36.5	167	21	Human secreted pro
3	852	36.5	167	22	Gene 13 human secr
4	852	36.5	167	22	Human secreted pro
5	470.5	20.2	418	17	Human neurotensin
6	404	17.3	410	19	Human type 2 neuro
7	404	17.3	410	21	Human NTRIP protel
8	403.5	17.3	353	15	G-protein coupled
9	403.5	17.3	353	17	G-protein coupled
10	370.5	15.9	319	19	Human neurotensin
11	364	15.6	395	22	Amino acid sequenc

12	363	15.6	405	21	AAV44641	Mouse growth hormo
13	363	15.6	405	22	AAV99186	Marine FM-3. Mus
14	363	15.6	412	22	AAV67803	Amino acid sequenc
15	363	15.6	415	21	AAV71296	Human orphan G pro
16	363	15.6	415	21	AAV02830	Human G protein co
17	363	15.6	415	22	AAV63353	Amino acid sequenc
18	363	15.6	415	22	AAV64297	Human GTP-binding
19	363	15.6	415	22	AAE03629	Human G-protein co
20	363	15.6	415	22	AAV67802	Amino acid sequenc
21	362	15.5	395	22	AAE03634	Rat G-protein coup
22	362	15.5	415	21	AAV52952	Human neurotensin-
23	362	15.5	415	22	AAV63366	Amino acid sequenc
24	361	15.5	415	22	AAV67805	Amino acid sequenc
25	361	15.5	415	22	AAV67804	Amino acid sequenc
26	355.5	15.2	412	21	AAV51145	Long form of motil
27	355.5	15.2	412	22	AAV62652	Amino acid sequenc
28	355.5	15.2	412	22	AAV68478	Human G protein co
29	349.5	15.0	412	21	AAV02854	Human G protein-co
30	346.5	14.8	403	21	AAV90638	Human growth hormo
31	346.5	14.8	403	21	AAV44642	Human FM-3. Homo
32	346.5	14.8	403	22	AAV99185	Human G-protein co
33	346.5	14.8	426	22	AAE03628	Rat FM-3. Ratius
34	345.5	14.8	412	22	AAV99199	Rat G-protein coup
35	345.5	14.8	413	22	AAE03635	Rat G-protein coup
36	345.5	14.8	439	22	AAE03636	Human mutant G pro
37	344.5	14.8	403	21	AAV90673	The puffer fish mo
38	327.5	14.0	363	21	AAV54147	Amino acid sequenc
39	327.5	14.0	363	22	AAV68479	Amino acid sequenc
40	324.5	13.9	400	22	AAV68477	A canine growth ho
41	320	13.7	349	21	AAV69293	Pig growth hormo
42	310	13.3	353	18	AAV19608	Swine growth hormo
43	310	13.3	353	18	AAV19215	A mouse growth hor
44	310	13.3	364	21	AAV54565	
45	308	13.2	364	22	AAV97577	Rat growth hormone

ALIGNMENTS

RESULT 1
ID AAB63203 standard; Protein: 167 AA.
XX AC AAB63203;
XX DT 26-MAR-2001 (first entry)
XX DE
XX DE Gene 28 human secreted protein homologous amino acid sequence #129.
XX KW Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
XX KW antithrombotic; antiproliferative; cytosolic; cardiac; vasotropic;
XX KW cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
XX KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;
XX KW rheumatoid arthritis; hyperproliferative disorder; cardiac arrest;
XX KW cardiovascular disorder; cerebrovascular disorder; cerebral ischemia;
XX KW angiogenesis; nervous system disorder; Alzheimer's disease; infection;
XX KW ocular disorder; corneal infection; wound healing; skin aging;
XX KW food additive; preservative.
XX OS Homo sapiens.
XX PN W0200061629-A1.
XX PD 19-OCT-2000.
XX PF 06-APR-2000; 2000WO-US09071.
XX PR 09-APR-1999; 99US-0128694.
XX PR 20-JAN-2000; 2000US-0176931.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PA (ROSE/) ROSEN C A.

PI Ruben SM, Komatsoulis G;
 XX WPI: 2000-647420/62.
 DR Isolated nucleic acid molecule encoding a human secreted protein is
 XX used in preventing, treating or ameliorating a medical condition -
 PT Disclosure: Page 506-507; 533pp; English.
 XX
 XX AAF22373 to AAF22421 encode the human secreted proteins given in AAB63134
 CC to AAB63182. AAB63183 to AAB63231 represent more human secreted proteins
 CC and polypeptides homologous to them. Human secreted proteins have
 CC activities based on the tissues and cells the genes are expressed in.
 CC Examples of activities include: immunosuppressive; antiarthritic;
 CC antineumatic; antiproliferative; cytostatic; cardiant; vasotropic;
 CC cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;
 CC fungicide; and ophthalmological. The polynucleotides and proteins can be
 CC used to prevent, treat or ameliorate a medical condition in e.g. humans,
 CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are
 CC also used in diagnosing a pathological condition or susceptibility to a
 CC pathological condition. Disorders which are diagnosed or treated include
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular
 CC disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral
 CC ischaemia, angiodenesis, nervous system disorders e.g. Alzheimer's
 CC disease, infections caused by bacteria, viruses and fungi and ocular
 CC disorders e.g. corneal infection. The polypeptides can also be used to
 CC aid wound healing and epithelial cell proliferation, to prevent skin
 CC aging due to sunburn, to maintain organs before transplantation, for
 CC supporting cell culture of primary tissues, to regenerate tissues and in
 CC chemotaxis. The polypeptides can also be used as a food additive or
 CC preservative to increase or decrease storage capabilities. AAF22364 to
 CC AAF22372 and AAB63133 represent sequences used in the exemplification of
 CC the present invention.
 XX
 XX Sequence 167 AA:
 SO
 Query Match 36.5%; Score 852; DB 21; Length 167;
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 287 LIYVTLAVCMWPNQIRIRIAAKPKHDWTSYRAYMILPSETFYLSVYNPLITYV 346
 DB 1 LIYVTLAVCMWPNQIRIRIAAKPKHDWTSYRAYMILPSETFYLSVYNPLITYV 60
 QY 347 SSOQFRVFOVLCRSLQHANHEKRLRYHAHSTDSARFYQRLPLFASRRSSARTE 406
 DB 61 SSGQFRVFOVLCRSLQHANHEKRLRYHAHSTDSARFYQRLPLFASRRSSARTE 120
 QY 407 KIFLSTFQSEAPQSKQSLSLESLPNSGAKPANSAAENGFOHEHY 453
 DB 121 KIFLSTFQSEAPQSKQSLSLESLPNSGAKPANSAAENGFOHEHY 167
 RESULT 2
 AAB63204
 ID AAB63204 standard; Protein: 167 AA.
 XX
 XX AAB63204;
 AC
 XX
 XX 26-MAR-2001 (first entry)
 DT
 XX
 XX Human secreted protein sequence encoded by gene 28 SHQ ID NO:130.
 DE
 XX
 XX Human: secreted protein; diagnosis; immunosuppressive; antiarthritic;
 KW antirhumatic; antiproliferative; cytostatic; cardiant; vasotropic;
 KW cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;
 KW fungicide; ophthalmological; gene therapy; autoimmune disease; neoplasm;
 KW rheumatoid arthritis; hyperproliferative disorder; cardiac arrest;
 KW cardiovascular disorder; cerebrovascular disorder; cerebral ischaemia;
 KW angiodenesis; nervous system disorder; Alzheimer's disease; infection;
 KW ocular disorder; corneal infection; wound healing; skin aging;

KW food additive; preservative.
 XX
 XX Homo sapiens.
 OS
 XX WO200061629-A1.
 PN
 XX
 XX 19-OCT-2000.
 PD
 XX
 XX 06-APR-2000; 2000WO-US09071.
 PF
 XX
 XX 09-APR-1999; 99US-0128694.
 PR
 XX 20-JAN-2000; 2000US-0176931.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 PI Ruben SM, Komatsoulis G;
 XX
 XX WPI: 2000-647420/62.
 DR
 XX Isolated nucleic acid molecule encoding a human secreted protein is
 PT used in preventing, treating or ameliorating a medical condition -
 XX
 XX Disclosure: Page 507-508; 533pp; English.
 XX
 XX AAF22373 to AAF22421 encode the human secreted proteins given in AAB63134
 CC to AAB63182. AAB63183 to AAB63231 represent more human secreted proteins
 CC and polypeptides homologous to them. Human secreted proteins have
 CC activities based on the tissues and cells the genes are expressed in.
 CC Examples of activities include: immunosuppressive; antiarthritic;
 CC antineumatic; antiproliferative; cytostatic; cardiant; vasotropic;
 CC cerebroprotective; neurotropic; neuroprotective; antibacterial; vitruide;
 CC fungicide; and ophthalmological. The polynucleotides and proteins can be
 CC used to prevent, treat or ameliorate a medical condition in e.g. humans,
 CC mice, rabbits, goats, horses, cats, dogs, chickens or sheep. They are
 CC also used in diagnosing a pathological condition or susceptibility to a
 CC pathological condition. Disorders which are diagnosed or treated include
 CC autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
 CC disorders e.g. neoplasms of the breast or liver, cardiovascular
 CC disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral
 CC ischaemia, angiodenesis, nervous system disorders e.g. Alzheimer's
 CC disease, infections caused by bacteria, viruses and fungi and ocular
 CC disorders e.g. corneal infection. The polypeptides can also be used to
 CC aid wound healing and epithelial cell proliferation, to prevent skin
 CC aging due to sunburn, to maintain organs before transplantation, for
 CC supporting cell culture of primary tissues, to regenerate tissues and in
 CC chemotaxis. The polypeptides can also be used as a food additive or
 CC preservative to increase or decrease storage capabilities. AAF22364 to
 CC AAF22372 and AAB63133 represent sequences used in the exemplification of
 CC the present invention.
 XX
 XX Sequence 167 AA:
 SO
 Query Match 36.5%; Score 852; DB 21; Length 167;
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 287 LIYVTLAVCMWPNQIRIRIAAKPKHDWTSYRAYMILPSETFYLSVYNPLITYV 346
 DB 1 LIYVTLAVCMWPNQIRIRIAAKPKHDWTSYRAYMILPSETFYLSVYNPLITYV 60
 QY 347 SSOQFRVFOVLCRSLQHANHEKRLRYHAHSTDSARFYQRLPLFASRRSSARTE 406
 DB 61 SSGQFRVFOVLCRSLQHANHEKRLRYHAHSTDSARFYQRLPLFASRRSSARTE 120
 QY 407 KIFLSTFQSEAPQSKQSLSLESLPNSGAKPANSAAENGFOHEHY 453
 DB 121 KIFLSTFQSEAPQSKQSLSLESLPNSGAKPANSAAENGFOHEHY 167
 RESULT 3
 AAB75565

ID AAB75565 standard; Protein: 167 AA.
 XX AAB75565;
 AC
 XX 06-APR-2001 (first entry)
 DT
 XX Gene 13 human secreted protein homologous amino acid sequence #119.
 DE
 XX Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
 KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
 KW neurotropic; neuroprotective; antibacterial; virucide; fungicide;
 KW ophthalmological; vulnary; autoimmune disease; cardiovascular disorder;
 KW hyperproliferative disorders; cerebrovascular disorder; wound healing;
 KW nervous system disorder; ocular disorder; skin aging; chemotaxis;
 KW food additive.
 KW
 XX Homo sapiens.
 OS
 XX MO200077026-A1.
 PN
 XX 21-DEC-2000.
 PF
 XX 01-JUN-2000; 2000MO-US14973.
 PR
 XX 11-JUN-1999; 99US-0138630.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 XX
 PI Rosen CA, Ruben SM, Komatsoulis GA;
 DR WPI: 2001-071258/08.
 XX
 PT Nucleic acid molecules encoding human secreted proteins, used in
 PT preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
 PT Parkinson's diseases and cancers -
 XX
 PS Disclosure: Page 39; 542pp; English.
 XX
 CC Human secreted proteins AAB75506 - AAB75554 are encoded by polynucleotide
 CC sequences AAF64176 - AAF64224. The specification includes amino acid
 CC sequences AAB75555 - AAB75606 which represent fragments of the human
 CC secreted proteins, and protein sequences with which they share homology.
 CC The proteins and polynucleotides, their agonists and antagonists have
 CC activities dependent on the tissues and cells in which they are
 CC expressed, examples of these activities include; immunosuppressive;
 CC antirheumatic; antirheumatic; antiproliferative; cytostatic; cardiant;
 CC vasotropic; cerebroprotective; neurotropic; neuroprotective; antibacterial;
 CC virucide; fungicide; ophthalmological; and vulnary. The proteins,
 CC polynucleotides, agonists and antagonists can be used to treat or detect
 CC or diagnose various diseases and disorders including; autoimmune
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders
 CC e.g. neoplasms of the breast or liver, cardiovascular disorders
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
 CC infections caused by bacteria, viruses and fungi and ocular disorders
 CC e.g. corneal infection. The polypeptides can also be used to aid wound
 CC healing and epithelial cell proliferation, to prevent skin aging due to
 CC sunburn, to maintain organs before transplantation, for supporting cell
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
 CC polypeptides can also be used as a food additive or preservative to
 CC increase or decrease storage capabilities. Included in the invention are
 CC polynucleotide sequences AAF64167 - AAF64175 and peptide AAB75505 which
 CC are used in the isolation, identification and characterisation of the
 CC proteins of the invention.
 CC
 XX Sequence 167 AA;
 SO

Query Match 36.5%; Score 852; DB 22; Length 167;
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 287 LIYVTLAVGCMNQRIRMAAKPKHDWTSYPRAYMILLPESEFPYLSYINPLLYTV 346
 DB 1 LIYVTLAVGCMNQRIRMAAKPKHDWTSYPRAYMILLPESEFPYLSYINPLLYTV 60
 QY 347 SSQCFRRVFEVQVLCRISLQHANHEKRLRVHAHSTDSARFVORPLLFASRRQSSARTE 406
 DB 61 ssqcfrrvfvqlccrlslqhanhekrllrvhahstdsarfvrplllfssrrqsarrrte 120
 QY 407 KIFLSTFQSEAEFQSKSLSLEPNSGAKPANSANGFOHEHY 453
 DB 121 kiflstfqsaeepqskslslelpsngakpansaangfhehev 167
 RESULT 4
 ID AAB75566 standard; Protein: 167 AA.
 XX AAB75566;
 AC
 XX 06-APR-2001 (first entry)
 DT
 XX Human secreted protein sequence encoded by gene 13 SEQ ID NO:120.
 DE
 XX Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
 KW antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
 KW neurotropic; neuroprotective; antibacterial; virucide; fungicide;
 KW ophthalmological; vulnary; autoimmune disease; cardiovascular disorder;
 KW hyperproliferative disorders; cerebrovascular disorder; wound healing;
 KW nervous system disorder; ocular disorder; skin aging; chemotaxis;
 KW food additive.
 KW
 XX Homo sapiens.
 OS
 XX MO200077026-A1.
 PN
 XX 21-DEC-2000.
 PF
 XX 01-JUN-2000; 2000MO-US14973.
 PR
 XX 11-JUN-1999; 99US-0138630.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (ROSE/) ROSEN C A.
 XX
 PI Rosen CA, Ruben SM, Komatsoulis GA;
 DR WPI: 2001-071258/08.
 DR N-PSDB; AAF64188.
 XX
 PT Nucleic acid molecules encoding human secreted proteins, used in
 PT preventing, treating or ameliorating a disorder, e.g. Alzheimer's and
 PT Parkinson's diseases and cancers -
 XX
 PS Disclosure: Page 39; 542pp; English.
 XX
 CC Human secreted proteins AAB75506 - AAB75554 are encoded by polynucleotide
 CC sequences AAF64176 - AAF64224. The specification includes amino acid
 CC sequences AAB75555 - AAB75606 which represent fragments of the human
 CC secreted proteins, and protein sequences with which they share homology.
 CC The proteins and polynucleotides, their agonists and antagonists have
 CC activities dependent on the tissues and cells in which they are
 CC expressed, examples of these activities include; immunosuppressive;
 CC antirheumatic; antirheumatic; antiproliferative; cytostatic; cardiant;
 CC vasotropic; cerebroprotective; neurotropic; neuroprotective; antibacterial;
 CC virucide; fungicide; ophthalmological; and vulnary. The proteins,
 CC polynucleotides, agonists and antagonists can be used to treat or detect
 CC or diagnose various diseases and disorders including; autoimmune
 CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders
 CC e.g. neoplasms of the breast or liver, cardiovascular disorders
 CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
 CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
 CC infections caused by bacteria, viruses and fungi and ocular disorders
 CC e.g. corneal infection. The polypeptides can also be used to aid wound

CC healing and epithelial cell proliferation, to prevent skin ageing due to
 CC sunburn, to maintain organs before transplantation, for supporting cell
 CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
 CC polypeptides can also be used as a food additive or preservative to
 CC increase or decrease storage capabilities. Included in the invention are
 CC polynucleotide sequences AAF64167 - AAF64175 and peptide AAF75505 which
 CC are used in the isolation, identification and characterisation of the
 CC proteins of the invention.

XX Sequence 167 AA:

Query Match 36.5%; Score 852; DB 22; Length 167;
 Best Local Similarity 100.0%; Pred. No. 1.2e-80;
 Matches 167; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 287 LLYVTLAVCMENQIRIMAAKPKHMDTRSTFRAYMILLPSEFFYLSVINPLITY 346
 Db 1 Llyvtlavcmnpqirimaakpkhmdtrstfraymllpseffylssvinplitylv 60
 QY 347 SSQGFRRVFOVYCCRLSLQHANHEKRLVHAHSTDSARFYORPLLFASRROSSARTE 406
 Db 61 ssqgfrrvfyvccrlslqhanhekrtrlvahstdsarfyrpllfasrrgsartte 120
 QY 407 KIFLSTFQSEAEPOSKQSLSESLSPNSGAKPANSAAENGQEHV 453
 Db 121 kiflstfgseaeqsksgslsleslspnsagakpansaaengfgehev 167

RESULT 5

AAR98562
 ID AAR98562 standard; Protein; 418 AA.

XX AC AAR98562;

DT 07-NOV-1996 (first entry)

XX DE Human neurotensin receptor.

XX KW neurotensin receptor; antagonist; agonist; screening; treatment; ulcer;
 KW Parkinson's disease; depression; dementia; retrograde oesophagitis.

XX OS Homo sapiens.

XX PN JP08143597-A.

XX PD 04-JUN-1996.

XX PE 4-NOV-1994; 94JP-0289882.

XX PR 24-NOV-1994; 94JP-0289882.

XX PA (TAKE) TAKEDA CHEM IND LTD.

XX DR WPI; 1996-318958/32.

XX DR N-PSDB; AAT33127.

XX PT DNA encoding human neurotensin receptor protein - useful for
 PT screening for (ant)agonists used to treat, e.g. Parkinson's disease,
 PT depression, dementia, retrograde oesophagitis, ulcers, etc.

XX PS Claim 1; Page 20-21; 26pp; Japanese.

XX CC The present sequence is that of a human neurotensin receptor protein

CC The DNA (AAT33127) encoding it and the protein are useful for screening

CC for (ant)agonists used to treat Parkinson's disease, depression,
 CC dementia, retrograde oesophagitis, ulcers, etc..

XX SQ Sequence 418 AA:

Query Match 20.2%; Score 470.5; DB 17; Length 418;
 Best Local Similarity 32.7%; Pred. No. 2.2e-40;

Matches 115; Conservative 66; Mismatches 136; Indels 35; Gaps 10;

QY 22 EFEVAT--WIKITLLVLIIFWGLGNSATIRVQVLOKRGY--LQKEVTDHMYSLAC 77
 Db 53 eldvntldyskvlvtaylalfvgtvgn--tvtafclarkelsqstsvhlgslal 110
 QY 78 SDILVFLIGMEFEYSITIMNDLTSSTYLSCKLHFLFEACSAITLHLVLSFERIAI 137
 Db 111 sdlltlllampvelynfivwhpafgdagorgyyflrdactyatalnvaslverylail 170
 QY 138 CHPRRYKAVSGPCQVKLLIGFWWTSAVLALPLIFANGTEPLVNVSHRGILNCNRSTR 197
 Db 171 chprkaktlmsrtkkfisaivlasallavpmlfmgqg-----nrsadg 216
 QY 198 HHDEPETSNSICT--NLSSRWTFQSSIFGAFVYLVYLVSAFECMMVMQVLMK--S 252
 Db 217 qh-----agvlvcvplhtatkvvlgvntlmstfpmvvasvIntllankltvmyrgaa 271
 QY 253 QKSL--AGTRPPOLRKSESESR--ARROTIIFLLIYVTLAVCMNPDIRIMAAK 309
 Db 272 eggvctvgsgh--stfamaiepgvqalrhgyrvlraavlaivvcwlpvhrllmfcyl 329
 QY 310 PKHMDTRSTFRAYMILLPSEFFYLSVINPLITYVSSOOFRRVFOVYVCC 361
 Db 330 sdegwcpflydfnylymvvtallfvestlplilylvsanfnhfiatlac 381

RESULT 6

AAM66103
 ID AAM66103 standard; Protein; 410 AA.

XX AC AAM66103;

DT 04-DEC-1998 (first entry)

XX DE Human type 2 neurotensin receptor protein.

XX KW Human; neurotensin type 2 receptor; hMT-R2; treatment; hormonal;
 KW neurological disorder; neurotensin; thermo-regulation disorder; stress;
 KW muscular contraction disorder; schizophrenia; analgesic; antipyretic.

XX OS Homo sapiens.

XX FH Key

XX FT Location/Qualifiers

XX FT 33..58 "transmembrane domain"

XX FT 71..91 "transmembrane domain"

XX FT 110..131 "transmembrane domain"

XX FT 155..175 "transmembrane domain"

XX FT 204..230 "transmembrane domain"

XX FT 297..315 "transmembrane domain"

XX FT 335..361 "transmembrane domain"

XX FT Domain

XX FT FR2760750-A1.

XX PD 18-SEP-1998.

XX PF 17-MAR-1997; 97FR-0003204.

XX PR 17-MAR-1997; 97FR-0003204.

XX PA (SNFI) SANOFI SA.

XX PI Caput D, Chalon P, Ferrara P, Vita N;

XX DR WPI; 1998-508932/44.

XX DR N-PSDB; AAV07655.


```

Db      311 lpyharrimycvppddawtdpnyhnyfymwntnlifvssavtprllynavssstfrikfll 370
Qy      357 QVLCGRSLQHANHE-KRLRVAHSTT 382
Db      371 eavv---slcgehhpmkrlpkpqspt 394

RESULT 8
AA048724
ID      AA048724 standard; Protein: 353 AA.
AC      AA048724;
XX      06-JUN-1996 (first entry)
DT      G-protein coupled rat neurotensin receptor protein.
DE      G-protein coupled receptor; ligand binding assay; transmembrane domain;
KW      psychotic disorder; schizophrenia; dopamine; AMP; adenosine; thrombin;
KW      muscarinic acetylcholine; adrenergic; endothelin; bombesin; endocrine;
KW      rhodopsin; opsin; odorant; cytomagalovirus.
XX      Rattus rattus.
OS      Rattus rattus.
PN      W09405695-A1.
XX      17-MAR-1994.
PD      09-SEP-1993; 93WO-US08528.
XX      10-SEP-1992; 92US-0943236.
PR      (UYNY ) UNITV NEW YORK STATE.
XX      Murphy RB, Schuster DI;
PI      WPI: 1994-101120/12.
DR      Polypeptides of G-coupled receptor proteins (GPRs) - useful for
PT      binding GPR ligands or modulating GPR binding
XX      Disclosure; Page 99-100; 160pp; English.
XX      Proteins AA048685-R48758 represent a range of G-protein coupled receptor
CC      proteins selected from CAMP, adenosine, muscarinic acetylcholine,
CC      adrenergic, thrombin, endothelin, bombesin, endocrine, rhodopsin, opsin,
CC      odorant, cytomagaloviral and other G-protein coupled receptors. The
CC      receptor proteins were used to design polypeptides, pref. based on the
CC      transmembrane domains, for use in G-protein coupled receptor ligand
CC      binding assays. The polypeptide fragments retain biological activity
CC      such as binding a GPR ligand or modulating GPR ligand binding to a GPR
CC      (see AA048759-R48758, AA050569-R50807 and AA089189-R89195 for examples
CC      of polypeptide fragments). The polypeptide fragments can be used in
CC      compositions for treating subjects suffering from a pathology related to
CC      a GPR abnormality e.g. a psychotic disorder such as schizophrenia.
XX      Sequence 353 AA:

Query Match      17.3%; Score 403.5; DB 15; Length 353;
Best Local Similarity 31.3%; Pred. No. 1.6e-33;
Matches 108; Conservative 59; Mismatches 133; Indels 45; Gaps 12;

Qy      30 KITLLIYLIIFFWGLIGNSATIRVQVLOKGY--LQKEVDHMSVSLACSDIIVLIGM 87
Db      1 kvltatylalifvgtvgsvt--aftlarkkslgsigtvnhpshlsalsdillllw-- 56

Qy      88 PMEFYSIIM-NPLJTSSTYSLCKLHTEFACSYATLLHVLTSFPRYTAICHPRYKAV 146
Db      57 -velynlwhpwafgd--agcrgyyflirdacysatalnvaaslsverylaichpfakel 113

Qy      147 SGPQVALLIGFVWVTSALVALPLFLFAMGTETPLVNVVSHKGLTCNRSSTRHHEDETSN 206

```

```

Db      114 msrtrtkkfisaiaiaaiaaiaipmlfclgq-----trsgdgtl-----Pg 154
Qy      207 MSITNTLSRRT--VFQSSIFGAFVYLVVLLSVAFMCMNMQVLM--KSQKSLAGGT 261
Db      155 glvcptvdatvkvvqivqntmsflfpmllvislntvankltmwvhaegqgryctvg 214
Qy      262 RPPQLRKS---ESESERT-ARROTIIFRLIIVVTLAVCMWPNQIRIRMAAKPKHDWTR 316
Db      215 thnglensftmriepgrvgalrhgvlvrlavafvcwlp-----ylcysdsgwt 268
Qy      317 SYFRAVMILLFSEFFYLSVINPLLYTVSSQOFRRVFOVLC 361
Db      269 flfafyngfymlnalfvssainpilylnlvsanirgvlstlac 313

RESULT 9
AA02696
ID      AA02696 standard; peptide: 353 AA.
AC      AA02696;
XX      12-NOV-1996 (first entry)
DT      G-protein coupled rat neurotensin receptor.
DE      G-protein coupled receptor; ligand binding assay; transmembrane domain;
KW      schizophrenia; dopamine; CAMP; adenosine; thrombin; adrenergic; opsin;
KW      muscarinic acetylcholine; endothelin; bombesin; endocrine; rhodopsin;
KW      odorant; cytomagalovirus; serotonergic.
XX      Rattus rattus.
OS      Rattus rattus.
PN      US5508384-A.
XX      16-APR-1996.
PD      10-SEP-1992; 92US-0943236.
XX      09-SEP-1993; 93US-0118270.
PR      10-SEP-1992; 92US-0943236.
XX      (UYNY ) UNITV NEW YORK STATE.
XX      Murphy RB, Schuster DI;
PI      WPI: 1996-208785/21.
DR      New dopamine receptor peptide - useful as antipsychotic agent, e.g.
PT      for treating schizophrenia
XX      Disclosure; Column 117-120; 184pp; English.
XX      Proteins AA02657-W02730 represent a range of G-protein coupled receptor
CC      (GPR) proteins selected from CAMP, adenosine, muscarinic acetylcholine,
CC      adrenergic, thrombin, endothelin, bombesin, endocrine, rhodopsin, opsin,
CC      odorant, cytomagaloviral and other GPR proteins. The receptor proteins
CC      were used to design polypeptides, pref. based on the transmembrane
CC      domains, for use in G-protein coupled receptor ligand binding assays.
CC      The polypeptide fragments retain biological activity such as binding a
CC      GPR ligand or modulating GPR ligand binding to a GPR (see
CC      AA002747-W02399 for examples of polypeptide fragments). The polypeptide
CC      fragments can be used in compositions for treating subjects suffering
CC      from a pathology related to a GPR abnormality e.g. a psychotic disorder
CC      such as schizophrenia.
XX      Sequence 353 AA:

Query Match      17.3%; Score 403.5; DB 17; Length 353;
Best Local Similarity 31.3%; Pred. No. 1.6e-33;
Matches 108; Conservative 59; Mismatches 133; Indels 45; Gaps 12;

```


[illegible]

```
Dd      153 ahvirmwgaivlatlflslpntshnglsq--llvpc-rg-----pydsal 195b

Qy      210 CTNLSSRWTVFOSSIFCAFVYVLVLLSVA--FMCMMMKOV-----IM 250c
        |         | : : : : : | : : : : |
Dd      196 c-----slvgpmdfykivlttallffclpmvtvislylllgirlrremrlq 243a
        |         | : : : : : | : : : : |

Qy      251 KSQGSILAGTRPPLQKKSESESESRTRRQTIIIFRLIVYTLANCMMPNPDIRIRMAAKP 310f
        ||         | : : : : : | : : : : | : : : : |
Dd      244 vevgyrktaaqetshrrlqld--rrirgqlkmlfaivavfgicwapfnadrimswlv 301e
        |         | : : : : : | : : : : | : : : : |

Qy      311 KHDWTRSYFRAYMILLPESEFFEFYLSSVINLPLTVSSQFRRVFVOVL-----CC-RLS 364a
        ||||| : : : : : | : : : : | : : : : |
Dd      302 ghs-teghihlaygcvhiasgfifflgsaaarpvlyslmsltrreflqalgigtqbchrrq 360b
        |         | : : : : : | : : : : | : : : : |

Qy      365 LQHANNHEKRLRVFAHSTTDS 384
        |         | : : : : : | : : : : | : : : : |
Dd      361 pyhgshn-----hairltfs 375
        |         | : : : : : | : : : : |
```

CC	RESULT_14
XX	AAB67803
XX	AAB67803 standard; Protein; 412 AA.
XX	
XX	
XX	AAB67803;
DT	29-JUN-2001 (first entry)
XX	
DE	Amino acid sequence of G-protein coupled receptor IG54A short version.
XX	
KW	Human; G-protein coupled receptor; IG54; IG54A; IG54B; schizophrenia;
KW	nervous system disorder; psychiatric disorder; Parkinson's disease;
KW	episodic paroxysmal anxiety; phobia; migraine; epilepsy; bulimia; stroke;
KW	cardiovascular disease; heart failure; angina pectoris; obesity; emesis;
KW	mobility disorder; myocardial infarction; hypertension; dyslipidemia;
KW	gastrointestinal disorder; inflammatory bowel disease; osteoporosis;
KW	inflammation; infection; pain; cancer; immune disorder; allergy; sepsis;
KW	gynecological disorder.
XX	
OS	Homo sapiens.
XX	
PN	WO200125269-A2.
XX	
PD	12-APR-2001.
XX	
PF	25-SEP-2000; 2000WO-EP09584.
XX	
PR	24-SEP-1999; 99EP-0203140.
PR	24-SEP-1999; 99NL-1013140.
PR	28-JUL-2000; 2000EP-0202683.
PR	31-JUL-2000; 2000US-0222047.
XX	
PA	(SOLV) SOLVAY PHARM BV.
XX	
PI	Deleersnijder W, Berger C, Loeken C, Nys G, Venema J;
XX	
DR	WPI: 2001-273566/28.
DR	N-PSDB: AAF80323.
XX	
PRT	New G-protein coupled receptors and the polynucleotides encoding them,
PRT	useful for preventing, ameliorating or correcting nervous system
PT	disorders, cardiovascular diseases, dyslipidemias, inflammations, pain
PT	or cancers -
XX	
PS	Claim 18; Page 81-82; 102pp; English.
XX	
CC	The present sequence represents the short version of a human G-protein
CC	coupled receptor designated IG54A. IG54 exists in two polymorphic forms,
CC	IG54A and IG54B. The IG54 receptors and IG54 polynucleotides are useful
CC	for preventing, ameliorating or correcting dysfunctions or diseases.
CC	These diseases include peripheral nervous system, psychiatric and central
CC	nervous system disorders (e.g. schizophrenia, episodic paroxysmal
CC	anxiety, phobia, Parkinson's disease, migraine, epilepsy, bulimia or
CC	stroke), cardiovascular diseases (e.g. heart failure, angina pectoris,

CC myocardial infarction or hypertension), dyslipidemias, obesity, emesis,
 CC gastrointestinal disorders (e.g. inflammatory bowel disease or motility
 CC disorders), osteoporosis, inflammations, infections (e.g. bacterial,
 CC fungal, protozoan or viral), pain, cancers, immune disorders, allergies,
 CC sepsis or gynecological disorders. Agonists or antagonists of IGs4 are
 CC effective with regard to disorders of the nervous system. Including the
 CC central and peripheral nervous systems, disorders of the gastrointestinal
 CC system, cardiovascular system, skeletal muscle, thyroid, lung or
 CC genitourinary system, or immunological disease. The IGs4 polynucleotides
 CC are useful as diagnostic reagents for detecting under-expression,
 CC overexpression or altered expression of IGs4.

XX Sequence 412 AA:

Query Match 15.6%; Score 363; DB 22; Length 412;

Best Local Similarity 28.0%; Pred. No. 3.4e-29;

Matches 97; Conservative 67; Mismatches 138; Indels 44; Gaps 10;

QY 35 LVYLLIFVWGLGNSATIRVTOVLQKKGYLQKEVTDHMYSLACSDILVFLGMPMEFYSI 94
 DB 47 VVYVPLIFVGVIGN---VIVCLVILQHGAMKTPNTYLLISLAVSDILVLLIGMLEVYE- 102
 QY 95 INNPILTSSYTLCKLHFFACSYATLLHVLTSFERIYAIChPRYKAVSGPCQVYL 154
 DB 103 mwrnypflfgpvcyfkfalfetvcfasllsttvsveryaillhpfaklqstrralr 162
 QY 155 LIGFWWTSALVALPLIFAMGTEPLVNPVSHRGILTCRRSSRRHHEQETS---NMSICT 211
 DB 163 IIGVWGFVLSLIP-----tstsh-----gikfhyfngslvpsatct 202
 QY 212 NLSSRMT---VFOSISFGAFVYLVVLSVAFMCMNMQVLKSGKSLAGCTRPQLRK 268
 DB 203 vikpmwlynfliqvt---stilyllp-mtvlsvlylmalitkkslead-----e 250
 QY 269 SESESRARROTIIFLRILVTVLAVCMNPNOIRIMAANKPHDWTSTRFRAYMILLPF 328
 DB 251 gnaaigrpcksvnkmflvlfavlcwaphndrlfssf--veesesiavfvlhv 308
 QY 329 SEFFYLSVINPLTYVSSQCFRRVFOVLCRSLQHANHEKRL 374
 DB 309 sgvfilyssavnpilyllstirfgaafgnvissfhkqwsqndpql 354

RESULT 15

AAV71296

ID AAY71296 standard; Protein: 415 AA.

AC AAY71296;

XX 02-NOV-2000 (first entry)

XX Human orphan G protein-coupled receptor hrup6.

KW Human, orphan G protein-coupled receptor; GPCR; hrup6; drug screening;
 transmembrane receptor; signal cascade.

OS Homo sapiens.

XX WO200031258-A2.

XX 02-JUN-2000.

XX 13-OCT-1999; 99WO-US23687.

XX 20-NOV-1998; 98US-0109213.

XX 16-FEB-1999; 99US-0120416.

XX 26-FEB-1999; 99US-0121852.

XX 12-MAR-1999; 99US-0123946.

XX 12-MAR-1999; 99US-0123949.

XX 28-MAY-1999; 99US-0136436.

XX 28-MAY-1999; 99US-0136437.

PR 28-MAY-1999; 99US-0136567.
 PR 28-MAY-1999; 99US-0137127.
 PR 28-MAY-1999; 99US-0137131.
 PR 29-JUN-1999; 99US-0141448.
 PR 29-SEP-1999; 99US-0156555.
 PR 29-SEP-1999; 99US-0156633.
 PR 29-SEP-1999; 99US-0156634.
 PR 29-SEP-1999; 99US-0156653.
 PR 01-OCT-1999; 99US-0157280.
 PR 01-OCT-1999; 99US-0157281.
 PR 01-OCT-1999; 99US-0157282.
 PR 01-OCT-1999; 99US-0157293.
 PR 01-OCT-1999; 99US-0157294.
 PR 12-OCT-1999; 99US-0416760.
 PR 12-OCT-1999; 99US-0417044.

XX (AREN-) ARENA PHARM INC.

XX Chen R, Dang HT, Liaw CW, Lin I;

XX WPI: 2000-400068/34.

XX DR N-PSDB; AAD01123.

XX Novel human orphan G protein-coupled receptors and the encoding cDNAs
 for use in the identification of G protein-coupled receptor agonists -

PS Claim 22; Page 57-59; 102pp; English.

CC The present amino acid sequence is the hrup6, an endogenous human
 CC orphan G protein-coupled receptor (GPCR). The full length hrup6 cDNA
 CC was cloned by RT-PCR using human thymus cDNA as template.

CC The orphan GPCR of the invention, like all GPCRs has seven transmembrane
 CC alpha helices with an extracellular N-terminus and an intracellular
 CC C-terminus. However, no endogenous ligands has yet been identified for
 CC the proteins of the invention. The orphan GPCRs may be used in the
 CC identification of their endogenous ligands, and to screen potential GPCR
 CC agonists and antagonists for use as pharmaceutical agents. The proteins
 CC may also be used in the study of GPCR-mediated signalling cascades, and
 CC to elucidate their precise role in normal and diseased human conditions.
 CC Nucleic acid encoding human orphan GPCRs may be used for tissue
 CC localisation expression analysis to provide information about their
 CC function in healthy and pathological states.

XX Sequence 415 AA:

Query Match 15.6%; Score 363; DB 21; Length 415;

Best Local Similarity 28.0%; Pred. No. 3.4e-29;

Matches 97; Conservative 67; Mismatches 138; Indels 44; Gaps 10;

QY 35 LVYLLIFVWGLGNSATIRVTOVLQKKGYLQKEVTDHMYSLACSDILVFLGMPMEFYSI 94
 DB 50 VVYVPLIFVGVIGN---VIVCLVILQHGAMKTPNTYLLISLAVSDILVLLIGMLEVYE- 105
 QY 95 INNPILTSSYTLCKLHFFACSYATLLHVLTSFERIYAIChPRYKAVSGPCQVYL 154
 DB 106 mwrnypflfgpvcyfkfalfetvcfasllsttvsveryaillhpfaklqstrralr 165
 QY 155 LIGFWWTSALVALPLIFAMGTEPLVNPVSHRGILTCRRSSRRHHEQETS---NMSICT 211
 DB 163 IIGVWGFVLSLIP-----tstsh-----gikfhyfngslvpsatct 205
 QY 212 NLSSRMT---VFOSISFGAFVYLVVLSVAFMCMNMQVLKSGKSLAGCTRPQLRK 268
 DB 206 vikpmwlynfliqvt---stilyllp-mtvlsvlylmalitkkslead-----e 253
 QY 269 SESESRARROTIIFLRILVTVLAVCMNPNOIRIMAANKPHDWTSTRFRAYMILLPF 328
 DB 254 gnaaigrpcksvnkmflvlfavlcwaphndrlfssf--veesesiavfvlhv 311
 QY 329 SEFFYLSVINPLTYVSSQCFRRVFOVLCRSLQHANHEKRL 374
 DB 312 sgvfilyssavnpilyllstirfgaafgnvissfhkqwsqndpql 357

Wed Jan 9 08:51:39 2002

us-09-635-521a-2.rag

Page 11

Search completed: January 8, 2002, 23:03:24
Job time: 2374 sec

